Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR3005-2
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR3005-2 is an investigational small molecule drug developed by Boryung Pharmaceutical, studied as a component of a fixed-dose combination therapy for the treatment of type 2 diabetes mellitus. It has been evaluated in phase 1 clinical trials to compare its pharmacokinetics and safety when administered alone versus as part of the fixed-dose combination product "BR3005" or co-administered with "BR3005-1". The specific mechanism of action, molecular target, and detailed composition have not been disclosed in public sources. The drug is administered orally and is being developed within the therapeutic area of endocrinology and metabolic diseases[1][2][3][4].
- Other names
- BR3005-2BR-3005-2BR 3005-2
Beyond the preview
Go deeper on BR3005-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR3005-2.